Related Experiment Video
Updated: Jul 6, 2026
The Influence of Liver Resection on Intrahepatic Tumor Growth
Published on: April 9, 2016
Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line
Leda Roncoroni1, Luca Elli, Ersilia Dolfini
1Center for Prevention and Diagnosis of Celiac Disease, IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy.
Background/Aims:
Cholangiocarcinoma is a devastating tumour with a poor prognosis. An efficient therapy is unavailable in unoperable patients and new drugs are widely sought for and required. Resveratrol (RES) is a natural molecule with a reported anticancer effect, evaluated on different tumour cell lines. We tested the efficacy of RES on a cholangiocarcinoma cell line for the first time.
Methods:
We used the human SK-ChA-1 cell line, cultured in the classical two-dimensional model and in the three-dimensional spheroids. After RES exposure morphology, cell viability (colony-forming assay), lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and cancer antigen (CA) 19-9 medium releases, cellular transglutaminase activity, karyotype and cell cycle were evaluated.
Results:
Resveratrol inhibited cell growth in both the cell culture systems used (from -15 to -80% vs untreated controls) and induced a 40-fold increase of LDH and ALP activities in the culture medium. Also, transglutaminase (TG) activity increased in the cell lysates, together with a cell cycle perturbation characterised by an accumulation in the G(1)/S phase. Karyotype and CA 19-9 expression were not influenced by the treatment.
Conclusions:
The observed cytotoxic effect of RES on the human cholangiocarcinoma SK-ChA-1 cell line cultured two- and three-dimensionally suggests to further analyse its chemotherapic/chemopreventive possibilities for this kind of cancer.
Insights
Resveratrol (RES) demonstrated significant cytotoxic effects on cholangiocarcinoma cells, inhibiting growth and altering cell cycle phases. This natural compound shows promise as a potential chemotherapeutic agent for this aggressive cancer.
Area of Science:
- Oncology
- Natural Product Chemistry
- Cell Biology
Background:
- Cholangiocarcinoma (CCA) is an aggressive cancer with limited treatment options.
- New therapeutic strategies are urgently needed for unresectable CCA.
- Resveratrol (RES), a natural polyphenol, exhibits known anticancer properties.
Purpose of the Study:
- To evaluate the efficacy of Resveratrol (RES) on a human cholangiocarcinoma cell line.
- To investigate the effects of RES on cell viability, proliferation, and cell cycle.
- To assess RES as a potential therapeutic agent for cholangiocarcinoma.
Main Methods:
- Human SK-ChA-1 cholangiocarcinoma cell line cultured in 2D and 3D models.
- Assessment of cell morphology, viability (colony-forming assay), and cell cycle.
- Measurement of lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and transglutaminase (TG) activity.
- Analysis of karyotype and cancer antigen (CA) 19-9 release.
Main Results:
- RES significantly inhibited cholangiocarcinoma cell growth by 15-80% in both 2D and 3D cultures.
- RES induced a 40-fold increase in LDH and ALP levels in the culture medium.
- RES treatment led to increased TG activity and cell cycle arrest at the G1/S phase.
Conclusions:
- Resveratrol exhibits a notable cytotoxic effect on human cholangiocarcinoma cells.
- The findings support further investigation into RES for cholangiocarcinoma chemoprevention and chemotherapy.
- RES demonstrates potential as a novel therapeutic agent for cholangiocarcinoma.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...